Skip to main content
. 2011 Jan;178(1):336–344. doi: 10.1016/j.ajpath.2010.11.023

Figure 6.

Figure 6

In vivo effects of the combination between rapamycin and LY294002. Rapamycin (1.5 mg/kg daily) and LY294002 (25 mg/kg three times a week) were administrated from day 3 to day 22. A: Morphometric analysis showing the distribution of tumor tissue surface values for the three groups of mice for both cell lines. In STC-1 tumor–bearing mice, rapamycin alone strongly decreased tumor tissue surface. Four of the five mice treated with the combination rapamycin and LY294002 exhibited a tumor tissue surface lower than the mean surface observed with rapamycin alone. In GLUTag tumor–bearing mice, three of the five mice treated with rapamycin alone exhibited a reduced tumor tissue surface, whereas the combination rapamycin and LY294002 induced a significant decrease of tumor tissue surface. B: Representative immunostaining for VEGF (arrows) in tumor nodules of each group of mice (original magnification, ×10). C: The expression of VEGF was lower when the combination rapamycin and LY294002 were used to treat the mice (*P < 0.05).